for pulmonary function and radiological outcomes before and after treatment. Results -24 patients were treated with Rituximab. Their physiological parameters had failed to improve 10 despite other immunomodulatory agents with a mean change in FVC prior to therapy of -3.3% (95% CI, -5. 6 11 to -1.1%) and mean DL CO change of -4.3% (95% CI, -7.7 to -0.9%). After Rituximab, radiology remained 12 stable or improved for 11, while worsening was observed in 9 patients. The decline in FVC was halted 13 following treatment, with a mean change of +4.1% (95% CI, 0.9 to 7.2%), while DL CO Evidence for this approach is based on institutional experiences, with no randomised, controlled trials yet 10 published.
11
The CTDs are heterogeneous processes characterised by autoimmune-mediated inflammation targeting highlighted other mechanisms, which are being further investigated (6).
17
It is recognised that all patients with CTDs are at risk of ILD, some more so than others (5). While this ILD 18 may be subclinical, having been identified through both radiological appearances and lung function 19 abnormalities in 33-57% of CTD patients with no respiratory symptoms (7-10), 5-80% of patients go on to 20 develop clinically significant lung disease within 3 years, with variation depending on the specific CTD. The 21 radiological and histological pattern of ILD described varies depending on the underlying CTD
22
(Supplementary Table S1 ), reflecting the heterogeneity of these conditions. 23 The Bristol Interstitial Lung Disease service runs a combined service with the Rheumatology CTD team to 1 manage patients with progressive lung disease and over the last 5 years has developed extensive 2 experience managing these patients with immunosuppression; typically including oral immunomodulatory immunomodulatory treatment. This is a report of our experience. Rheumatoid arthritis were excluded due to the distinct pattern of ILD observed in this group.
17
Hospital records were reviewed to identify, pulmonary function tests (PFT) performed 5 to 7 months prior 18 to Rituximab, in the 4 weeks immediately before treatment and 6 to 12 months following treatment.
19
Where relevant, the same approach was taken to PFTs prior to, at treatment with and following 20 cyclophosphamide therapy. High resolution computed tomograms (HRCT) of the chest were identified 21 from time of treatment and during follow-up. Patients were followed for a median of 29.6 months (16.7).
22
All PFT measurements were performed within the same respiratory physiology laboratory. 23 This clinical review was performed with full ethical approval (Reference 15/EE/0023). according to the visual estimation of extent of involvement described by Oda et al (12) . Change, compared 6 with baseline imaging, after treatment was assessed and categorised as: improved, stable or worsened.
7
The κ value for intra-rater agreement for extent of disease was 0.55, with a value of 0.92 for interval of follow-up after treatment was 29.6 months (16.7). Biopsy had been performed in a total of 11 patients.
22
Patient characteristics are shown in Table 1.   23   24 These patients were all managed under the Bristol CTD-ILD service and all had a diagnosis of CTD-ILD. Twenty two patients had positive serology for autoimmune markers (Supplementary Table S2 Thirteen patients (9 female) were identified from their clinico-serological phenotype with myositis or the 10 anti-synthetase syndrome, with a mean age of 53.5 yrs (SD 13.2). Seven of these were former smokers. When comparing patients with myositis or anti-synthetase syndrome with the remaining group, there were 24 significant differences in the response to treatment. FVC change after treatment was greater in the 25 myositis sub-group (p=0.002), as was improvement in DL CO (p=0.009) ( Table 2 ). There were no other 1 significant between group differences. The four patients in whom no autoantibody was identified We report here our experience of Rituximab in CTD-ILD in a significant number of patients, including an 10 identified cohort with CTD-myositis/overlap syndromes. This report adds to limited published data for use 11 of B-cell depletion as treatment in this difficult disease group.
12
The decision to treat is multi-factorial, guided by a combination of respiratory parameters and also Our data demonstrates, consistent with previously published series, a numerical improvement in FVC, with 1 stability of DL CO , however no impact was seen on radiological appearances. It is important to highlight that 2 these improvements were only clinically significant in four patients. These "responders" were patients 3 with myositis or anti-synthetase syndrome-related lung disease and this group appear to respond 4 particularly well to treatment, with greater improvement in FVC and DL CO compared to the non-myositis 5 group. 6 The limitations to our data are their observational nature, and the heterogeneity of data captured in the 7 course of disease. Despite this, we have observed statistically significant benefit in these patients and 8
clinically relevant benefit in a subgroup. In conclusion, we present here our experience using Rituximab for treatment-refractory CTD-ILD. is promising but remains to be defined and our data highlights the need for more research to identify those 7 patients who will have the best response to treatment. 
